Skip to main content

Table 3 Univariate and multivariate analysis of overall survival

From: The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease

 

Univariate analysis

Multivariate analysis

HR (95%CI)

p value

HR (95%CI)

p value

sex

1.78(0.90–3.52)

0.09

1.30(0.62–2.73)

0.49

age (years)

0.66(0.33–1.32)

0.24

  

smoking

1.45(0.71–2.89)

0.29

  

T stage

0.27(0.12–0.57)

0.001

0.29(0.12–0.70)

0.006

N stage

0.53(0.26–1.06)

0.07

0.55(0.26–1.16)

0.12

EGFR mutation

1.25(0.67–2.34)

0.48

  

No. mets

0.99(0.51–1.99)

0.99

  

No. mets. Organs

0.27(0.09–0.77)

0.02

1.01(0.27–4.30)

0.92

lung mets

1.91(0.89–4.10)

0.09

2.0(0.72–6.99)

0.11

bone mets

0.95(0.46–1.95)

0.89

  

adrenal gland mets

1.94(0.46–8.17)

0.35

  

brain mets

1.68(0.84–3.36)

0.14

  

LN mets

2.05(1.02–4.10)

0.04

1.80(0.82–3.96)

0.15

Osimertinib

1.07(0.31–3.71)

0.91

  

LCT

1.39(0.43–4.52)

0.58

0.37(0.12–1.16)

0.09

  1. Abbreviation: LCT local consolidative therapy, No number, mets metastasis, LN lymph node